Source: Eur Respir J 2014; 44: 289-296



Rating:

Share or cite this content

Citations should be made in the following way:
Camus Philippe, von der Thüsen Jan, Hansell David M., Colby Thomas V.. Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs?. Eur Respir J 2014; 44: 289-296

Member's Comments

No comment yet.

Related content which might interest you: Pleuroparenchymal fibroelastosis: what have we learned from lung transplantation? Source: International Congress 2017 – ME10 Pleuroparenchymal fibroelastosis: what have we learned from lung transplantation? Year: 2017 ME10 Pleuroparenchymal fibroelastosis: what have we learned from lung transplantation? Source: Milan 2017 - Educational material Year: 2017 Pleuroparenchymal fibroelastosis: report of 4 cases Source: International Congress 2017 – Rare diseases Year: 2017 Pleuroparenchymal fibroelastosis from a consecutive database: a rare disease entity? Source: Eur Respir J 2015; 45: 1183-1186 Year: 2015 Pleuroparenchymal fibroelastosis - clinical analysis of 22 cases Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes Source: Eur Respir J 2012; 40: 377-385 Year: 2012 Pleuroparenchymal fibroelastosis as a manifestation of chronic lung rejection? Source: Eur Respir J 2013; 41: 243-245 Year: 2013 The health status in idiopathic pleuroparenchymal fibroelastosis Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Case 2: Is it left ventricular dysfunction or PAH? Source: International Congress 2017 – CC6 Is it truly pulmonary arterial hypertension? Year: 2017 Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents Source: Eur Respir J 2014; 44: 523-527 Year: 2014 Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Architectural remodelling in idiopathic interstitial pneumonias: fibrosis or fibroelastosis? Source: Eur Respir J 2004; 24: Suppl. 48, 557s Year: 2004 Treatment with nintedanib in patients with pleuroparenchymal fibroelastosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Source: Eur Respir Rev 2015; 24: 375-377 Year: 2015 The thoracic cage becomes flattened in the progression of pleuroparenchymal fibroelastosis Source: Eur Respir Rev 2014; 23:263-266 Year: 2014 Severe pulmonary hypertension: walking through new paths to revisit an old field Source: Eur Respir J 2002; 20: 509-510 Year: 2002 Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Source: Breathe 2016; 12: 130-138 Year: 2016 Clinical courses of asymptomatic patients with mild idiopathic pleuroparenchymal fibroelastosis Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018 Treatment of right heart failure on pulmonary arterial hypertension: is going left a step in the right direction? Source: Eur Respir Rev 2009; 19: 4-6 Year: 2010 Lost in translation: Does radiological evidence of right ventricular strain in acute pulmonary embolism trigger echocardiographic follow-up? Source: Annual Congress 2013 –Pulmonary circulation: acute pulmonary tromboembolism Year: 2013